MA-VERACODE
23.5.2023 17:27:28 CEST | Business Wire | Press release
Veracode, a leading provider of intelligent software security solutions, has been positioned as a 10-time Leader in the 2023 Gartner Inc. Magic Quadrant for Application Security Testing—an in-depth evaluation of the market’s competitors. The company has been recognized as a Leader in the report every single time since it was first published.
With independent feedback and ratings from customer reviews culminating in a 97 percent “willingness to recommend” (based on 61 reviews, as of 31 July 2022), Veracode was also positioned as a Gartner Peer Insights™ Customers’ Choice for Application Security Testing.
Sam King, Chief Executive Officer at Veracode, said, “For more than 17 years, we have had an unrelenting commitment to making secure software a competitive advantage for our customers. Our continued position as a Leader in the Gartner Magic Quadrant, combined with our recognition as a Customers’ Choice, we feel demonstrates the trust placed in us every day by developers, security teams, and business leaders worldwide. We are proud to say that Veracode was one of the pioneers of application security and now we are propelling the category into the future: intelligent software security.”
The Head of Application Security at a banking company reviewing Veracode in Gartner Peer Insights™ said, “Of all the companies that carry out POCs (Proof of Concepts)...only Veracode proves to be a solid and senior company or enough to put in our financial institution." A security analyst at another firm commented, “In order for a product to be successful, it needs to do two things right, ‘product performance’ and ‘support’. Veracode gives you the best of both worlds, a great product with great support.”
Protecting the Software Supply Chain
Veracode offers EU and UK Support through its dedicated European Region, an EU instance that allows European organizations to address data residency concerns. The company has also achieved the US Federal Risk and Authorization Management Program (FedRAMP), which makes multiple tools available to US federal agencies that want to find and fix software supply chain vulnerabilities in accordance with compliance mandates. Veracode is the only software composition analysis vendor listed in the FedRAMP marketplace.
King said, “Increased reliance on third-party code, along with emerging regulations for software security and data compliance, are some of our customers’ greatest challenges. To alleviate the pressure on organizations, our proprietary database tracks open-source risk and our platform provides continuous scanning through multiple tools, including container security, infrastructure-as-code (IaC) scanning, and Software Bill of Materials (SBOM) capabilities.”
Veracode’s recent addition of Peer Benchmarking—a new self-service capability that allows organizations to measure their flaw and remediation performance against industry peers—also enables security leaders to assess the impact of their investments and demonstrate value to the business.
Strength of Vision: Delivering Capabilities Against Customer Needs
In the past year, Veracode has also made two significant acquisitions, to which the company credits its position in the report. Firstly, the acquisition of the Germany-based Crashtest Security tool enhanced Veracode’s existing dynamic analysis and penetration testing capabilities for web apps and application programming interfaces (APIs), as well as broadening customer access globally. More recently, the acquisition of auto-remediation technology from Jaroona, a 2021 Gartner® Cool Vendor™ for DevSecOps, enabled the launch of Veracode Fix. The new AI-powered product automatically suggests remediations for security flaws found in code and open-source dependencies.
Brian Roche, Chief Product Officer at Veracode, said, “One of the biggest pain points our customers express is mitigating intensifying threat against an expanding attack surface, while accelerating development velocity and minimizing costs. We’ve invested heavily in our platform over the past year to develop automated solutions that remove friction for developers and provide security teams with a comprehensive view of risk. The launch of Veracode Fix addresses the need to broaden our focus from application security testing to intelligent software security.”
To download a complimentary copy of the full 2023 Gartner Magic Quadrant Report, visit the Veracode website.
To learn more about intelligent software security from Veracode, please visit: https://www.veracode.com/products
1Gartner, Magic Quadrant for Application Security Testing, Mark Horvath, Dale Gardner, Manjunath Bhat, Ravisha Chugh, Angela Zhao, 17 May 2023.
2Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, September 30, 2022.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant, Cool Vendors and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Prompted by powerful AI trained by trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
